Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00060931 |
Evaluation of the effect of two different antihypertensive treatments on control of glucose in Type II diabetic patients with high blood pressure
Condition | Intervention | Phase |
---|---|---|
Non-Insulin-Dependent Diabetes Mellitus Hypertension |
Drug: carvedilol Drug: metoprolol |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Double-Blind, Multicenter Study Comparing the Effects of Carvedilol and Metoprolol on Glycemic Control in Hypertensive Patients With Type II Diabetes Mellitus. |
Estimated Enrollment: | 1210 |
Study Start Date: | June 2001 |
Ages Eligible for Study: | 30 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
United States, Alabama | |
GSK Investigational Site | |
Columbia, Alabama, United States, 35051 | |
GSK Investigational Site | |
Birmingham, Alabama, United States, 35294-2041 | |
GSK Investigational Site | |
Birmingham, Alabama, United States, 35211 | |
GSK Investigational Site | |
Mobile, Alabama, United States, 36608 | |
United States, Connecticut | |
GSK Investigational Site | |
Derby, Connecticut, United States, 06418 | |
GSK Investigational Site | |
Hartford, Connecticut, United States, 06106 | |
GSK Investigational Site | |
Farmington, Connecticut, United States, 06030 - 1410 | |
GSK Investigational Site | |
New Britain, Connecticut, United States, 06050 | |
United States, Delaware | |
GSK Investigational Site | |
Newark, Delaware, United States, 19713 | |
United States, District of Columbia | |
GSK Investigational Site | |
Washington, District of Columbia, United States, 20037 | |
GSK Investigational Site | |
Washington, District of Columbia, United States, 20422 | |
United States, Florida | |
GSK Investigational Site | |
Miami, Florida, United States, 33133 | |
GSK Investigational Site | |
Tamarac, Florida, United States, 33321 | |
GSK Investigational Site | |
Tampa, Florida, United States, 33614 | |
GSK Investigational Site | |
Melbourne, Florida, United States, 32901 | |
GSK Investigational Site | |
Miami, Florida, United States, 33176 | |
GSK Investigational Site | |
Miami, Florida, United States, 33136 | |
GSK Investigational Site | |
Fort Meyers, Florida, United States, 33907 | |
GSK Investigational Site | |
Ocala, Florida, United States, 34471 | |
GSK Investigational Site | |
Fort Lauderdale, Florida, United States, 33308 | |
GSK Investigational Site | |
Miami, Florida, United States, 33156 | |
GSK Investigational Site | |
Ocala, Florida, United States, 34474 | |
GSK Investigational Site | |
Saint Petersberg, Florida, United States, 33705 | |
GSK Investigational Site | |
Jacksonville, Florida, United States, 32216 | |
GSK Investigational Site | |
Coral Gables, Florida, United States, 33134 | |
GSK Investigational Site | |
Hollywood, Florida, United States, 33023 | |
GSK Investigational Site | |
Inverness, Florida, United States, 34452 | |
GSK Investigational Site | |
Gainesville, Florida, United States, 32605 | |
GSK Investigational Site | |
Sarasota, Florida, United States, 34239 | |
GSK Investigational Site | |
Pembroke Pines, Florida, United States, 33024 | |
GSK Investigational Site | |
Fort Lauderdale, Florida, United States, 33316 | |
GSK Investigational Site | |
Hollywood, Florida, United States, 33021 | |
United States, Georgia | |
GSK Investigational Site | |
Augusta, Georgia, United States, 30901 | |
GSK Investigational Site | |
Savannah, Georgia, United States, 31406 | |
GSK Investigational Site | |
Fayetteville, Georgia, United States, 30214 | |
GSK Investigational Site | |
Lawrenceville, Georgia, United States, 30045 | |
United States, Illinois | |
GSK Investigational Site | |
West Evanston, Illinois, United States, 60202 | |
GSK Investigational Site | |
Chicago, Illinois, United States, 60616 | |
United States, Indiana | |
GSK Investigational Site | |
Wabash, Indiana, United States, 46992 | |
GSK Investigational Site | |
Newburgh, Indiana, United States, 47630 | |
United States, Kentucky | |
GSK Investigational Site | |
Lexington, Kentucky, United States, 40508 | |
United States, Louisiana | |
GSK Investigational Site | |
New Orleans, Louisiana, United States, 70112 | |
GSK Investigational Site | |
New Orleans, Louisiana, United States, 70121 | |
United States, Maine | |
GSK Investigational Site | |
Auburn, Maine, United States, 04210 | |
United States, Maryland | |
GSK Investigational Site | |
Baltimore, Maryland, United States, 21208 | |
GSK Investigational Site | |
Baltimore, Maryland, United States, 21204 | |
United States, Massachusetts | |
GSK Investigational Site | |
Worcester, Massachusetts, United States, 01610 | |
GSK Investigational Site | |
Boston, Massachusetts, United States, 02115 | |
GSK Investigational Site | |
Springfield, Massachusetts, United States, 01107 | |
GSK Investigational Site | |
Ayer, Massachusetts, United States, 01432 | |
GSK Investigational Site | |
Worcester, Massachusetts, United States, 01605 | |
GSK Investigational Site | |
Haverhill, Massachusetts, United States, 01831-2451 | |
United States, Michigan | |
GSK Investigational Site | |
Waterford, Michigan, United States, 48328 | |
United States, Mississippi | |
GSK Investigational Site | |
Gulfport, Mississippi, United States, 39501 | |
United States, New Jersey | |
GSK Investigational Site | |
Hackensack, New Jersey, United States, 07601 | |
GSK Investigational Site | |
Voorhees, New Jersey, United States, 08043 | |
GSK Investigational Site | |
Margate, New Jersey, United States, 08402 | |
GSK Investigational Site | |
Linwood, New Jersey, United States, 08221 | |
GSK Investigational Site | |
Sea Girt, New Jersey, United States, 08750 | |
United States, New York | |
GSK Investigational Site | |
Rochester, New York, United States, 14609 | |
GSK Investigational Site | |
Liverpool, New York, United States, 13088 | |
GSK Investigational Site | |
Scarsdale, New York, United States, 10583 | |
GSK Investigational Site | |
Williamsville, New York, United States, 14221 | |
GSK Investigational Site | |
Bronx, New York, United States, 10461 | |
GSK Investigational Site | |
Kingston, New York, United States, 12401 | |
GSK Investigational Site | |
Lancaster, New York, United States, 14043 | |
GSK Investigational Site | |
Tonawanda, New York, United States, 14150 | |
GSK Investigational Site | |
Buffalo, New York, United States, 14209 | |
GSK Investigational Site | |
Fulton, New York, United States, 13069 | |
GSK Investigational Site | |
New York, New York, United States, 10028 | |
GSK Investigational Site | |
Flushing, New York, United States, 11365 | |
GSK Investigational Site | |
Syracuse, New York, United States, 13202 | |
GSK Investigational Site | |
New Hyde Park, New York, United States, 11040 | |
GSK Investigational Site | |
New York, New York, United States, 10021 | |
GSK Investigational Site | |
Bronx, New York, United States, 10467 | |
United States, North Carolina | |
GSK Investigational Site | |
Winston-Salem, North Carolina, United States, 27103 | |
GSK Investigational Site | |
Statesville, North Carolina, United States, 28677 | |
GSK Investigational Site | |
Raleigh, North Carolina, United States, 27609 | |
GSK Investigational Site | |
Hickory, North Carolina, United States, 28601 | |
GSK Investigational Site | |
Wilmington, North Carolina, United States, 28412 | |
United States, Ohio | |
GSK Investigational Site | |
Cleveland, Ohio, United States, 44106 | |
GSK Investigational Site | |
Zanesville, Ohio, United States, 43701 | |
GSK Investigational Site | |
Canton, Ohio, United States, 44708 | |
GSK Investigational Site | |
Cincinnati, Ohio, United States, 45246 | |
GSK Investigational Site | |
Columbus, Ohio, United States, 43212 | |
United States, Pennsylvania | |
GSK Investigational Site | |
Morrisville, Pennsylvania, United States, 19067 | |
GSK Investigational Site | |
Erie, Pennsylvania, United States, 16505 | |
GSK Investigational Site | |
Connellsville, Pennsylvania, United States, 15425 | |
GSK Investigational Site | |
Philadelphia, Pennsylvania, United States, 19107 | |
GSK Investigational Site | |
Camp Hill, Pennsylvania, United States, 17011 | |
GSK Investigational Site | |
Pittsburgh, Pennsylvania, United States, 15206 | |
GSK Investigational Site | |
Pittsburgh, Pennsylvania, United States, 15241 | |
GSK Investigational Site | |
Philipsburgh, Pennsylvania, United States, 16966 | |
GSK Investigational Site | |
Downington, Pennsylvania, United States, 19335 | |
GSK Investigational Site | |
West Grove, Pennsylvania, United States, 19390 | |
United States, South Carolina | |
GSK Investigational Site | |
Summerville, South Carolina, United States, 29485 | |
United States, Tennessee | |
GSK Investigational Site | |
Jackson, Tennessee, United States, 38301 | |
GSK Investigational Site | |
Memphis, Tennessee, United States, 38163 | |
GSK Investigational Site | |
Nashville, Tennessee, United States, 37212 | |
GSK Investigational Site | |
Bristol, Tennessee, United States, 37620 | |
United States, Utah | |
GSK Investigational Site | |
White River Junction, Utah, United States, 05009 | |
United States, Virginia | |
GSK Investigational Site | |
Christiansburg, Virginia, United States, 24073 | |
GSK Investigational Site | |
Springfield, Virginia, United States, 22151 | |
GSK Investigational Site | |
Richmond, Virginia, United States, 23220 | |
GSK Investigational Site | |
Falls Church, Virginia, United States, 22044 | |
GSK Investigational Site | |
Salem, Virginia, United States, 24153 | |
GSK Investigational Site | |
Richmond, Virginia, United States, 23294 | |
GSK Investigational Site | |
Fredericksburg, Virginia, United States, 20401 |
Study Director: | GSK Clinical Trials, M.D. | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | 105517/347 |
Study First Received: | May 15, 2003 |
Last Updated: | October 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00060931 |
Health Authority: | United States: Food and Drug Administration |
Type 2 diabetes hypertension beta-blockers |
Metabolic Diseases Metoprolol succinate Diabetes Mellitus, Type 2 Vascular Diseases Diabetes Mellitus Endocrine System Diseases |
Endocrinopathy Metoprolol Metabolic disorder Glucose Metabolism Disorders Carvedilol Hypertension |
Vasodilator Agents Neurotransmitter Agents Sympatholytics Adrenergic Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Adrenergic alpha-Antagonists Cardiovascular Agents Antihypertensive Agents |
Pharmacologic Actions Autonomic Agents Therapeutic Uses Adrenergic beta-Antagonists Cardiovascular Diseases Adrenergic Antagonists Peripheral Nervous System Agents Anti-Arrhythmia Agents |